Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05328908
Title A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Bristol-Myers Squibb

colorectal adenocarcinoma


Regorafenib + Trifluridine-tipiracil hydrochloride

Nivolumab and relatlimab-rmbw

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

Additional content available in CKB BOOST